Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 4/20 | 0.56 |
| ▸ | PIM1 | P11309 | 3/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | NEK4 | P51957 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.56 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828163 | 1.00 | PTGS2 (0.66) | PTGS2PTGS1CISD1GSK3BPIM1 | |
| SCHEMBL5827750 | 0.92 | PTGS1 (0.59) | PTGS2PTGS1CISD1GSK3BPIM1 | |
| SCHEMBL5827747 | 0.92 | PTGS1 (0.59) | PTGS2PTGS1CISD1GSK3BPIM1 | |
| SCHEMBL5828164 | 0.86 | CSNK2A1 (0.49) | PTGS2PTGS1CISD1GSK3BPIM1 | |
| SCHEMBL3667218 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1CISD1GSK3BHPGD | |
| SCHEMBL3667216 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1CISD1GSK3BHPGD | |
| SCHEMBL8962138 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1CISD1GSK3BHPGD | |
| SCHEMBL8172394 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1CISD1GSK3BPIM1 | |
| SCHEMBL8172395 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1CISD1GSK3BPIM1 | |
| SCHEMBL6449258 | 0.77 | PIM1 (0.51) | PTGS2PTGS1CISD1GSK3BPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1385465-A4 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | INCYTE SAN DIEGO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | PTGS2 3074/4885PTGS1 2411/4885CISD1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.